Adverum Biotech doses first subject in phase 2 trial to treat wet AMD

Sep. 14, 2022 11:39 AM ETADVMBy: Dania Nadeem, SA News Editor2 Comments
  • Adverum Biotechnologies (ADVM) said on Wednesday the first subject had been dosed in the Phase 2 trial testing ixoberogene soroparvovec to treat wet age-related macular degeneration.
  • The trial is designed to assess the safety and efficacy of two dose levels of a single, in-office intravitreal injection of Ixo-vec for the treatment of wet AMD.
  • The trial, dubbed LUNA, primary endpoints are mean change in BCVA from baseline to one year and the incidence and severity of adverse events.

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.